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1. Introduction 
Biotherapeutics are among the fastest-growing segments of the pharmaceutical market. The 
packaging requirements for these therapeutics can be unique, primarily due to the 
multitude of factors that can influence the stability and overall potency of each particular 
therapeutic. Additionally, packaging has become a prominent concern in the healthcare 
industry due to the prevalence of medication errors, hospital acquired infections and 
potential for injury to the healthcare worker. The ability to provide these therapies in ready 
to use (RTU) containers would provide several advantages to both patients and clinicians: 
the RTU systems are closed containers, which minimize the risk of hospital-acquired 
infections; there are no reconstitution or admixture steps required, which minimize the risk 
of medication errors and healthcare worker exposure; and the RTU systems save time for 
the clinicians. However, the decision about drug formulation and packaging often needs to 
be made early in development when supplies of the drug are scarce.  
Many of the biotherapeutics sold today are monoclonal antibodies. This circumstance lends 
itself well to the development of immunoassays for assessment of the activity of the 
particular therapeutic antibody. ELISA (enzyme-linked immunosorbent assay), also known 
as EIA (enzyme immunoassay), based assays are the most common approach for 
development of an immunoassay. This methodology has been extensively reviewed 
elsewhere (Wild 2001; Lequin 2005). These assays are usually performed in 96-well plates, 
but advances in automated liquid handling and spectrophotometric and fluorescent plate 
readers provide for formats as large as 1536 wells. The assays are typically structured in 
three basic formats, depending on the design of the assay. These include: 1) antibody 
capture assays, or solid-phase coated with antigen; 2) antigen capture assays, or solid phase 
coated with antibody; and 3) sandwich assays, which leverage an antibody pair, with one 
antibody coating the solid phase and the other binding the antigen in solution. The choice of 
assay format is primarily dictated by the analyte to be detected. In cases where the analyte is 
a small molecule that is either intrinsically fluorescent or has a distinct absorption spectrum, 
an antigen capture assay might be most applicable. Alternatively, if an antibody pair is 
available for an analyte, the sandwich ELISA is most commonly used. Since biotherapeutics 
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are often antibodies themselves, this poses more of a challenge and usually an antibody 
capture assay is most appropriate. 
Traditional ELISA/EIA assays are only a subset of potential immunoassay applications. 
These plate-based assays can also be leveraged in a competitive format, to allow for 
comparison of a standard to a test article directly in a binding reaction (as opposed to 
interpolation from the response curve of a known standard in a traditional ELISA). 
Competitive binding reactions can also be utilized in non-plate assay systems as well. Cell-
based assays, using the same direct binding or competitive binding principles, can be used 
to assess the binding of antibodies or ligands to cell surface receptors. Often these assays 
provide a more physiological approach to the assessment of the bioactivity of the 
therapeutic. However, this technique usually requires chemical modification of the antibody 
or ligand to include a fluorescent tag or radioisotope for detection, as the traditional ELISA 
colorimetric signal generation via horseradish peroxidase (HRP) is usually not feasible with 
these types of assays. Alternative signal generation methods have been developed, such as 
electrochemiluminescence detection (Meso Scale Discovery), which provides a much greater 
dynamic range and sensitivity compared to HRP based signals (Zhao et al. 2004). 
Fluorescent bead-based technologies, such as those developed by Luminex and 
PerkinElmer’s AlphaScreen® are also alternatives to standard solid phase ELISAs (Kellar et 
al. 2006; Eglen et al. 2008). These are analogous to ELISA sandwich assays, but use 
suspended beads as the solid phase in the assay, rather than the plate surface. A caveat to 
bead-based assays and electrochemiluminescence, however, is the requirement for 
specialized equipment to perform the detection step. Nevertheless, there are multiple 
approaches and assay formats that can be used in developing an immunoassay for the 
characterization of a specific biotherapeutic. 
This study focuses on the development and use of biological assays for assessing the 
compatibility of therapeutic proteins with flexible drug containers, including the 
development of in-house immunoassays for two therapeutic antibodies, cetuximab and 
rituximab. Cetuximab (marketed under the trade name Erbitux®) is a humanized chimeric 
mouse monoclonal antibody directed against the epidermal growth factor receptor (EGFR). 
It was approved by the United States Food and Drug Administration (FDA) for the 
treatment of metastatic colorectal cancer in 2004, and also has indications for the treatment 
of head and neck squamous cell carcinomas. Binding of cetuximab to the soluble 
extracellular portion of EGFR (sEGFR) has been previously demonstrated in vitro and the 
crystal for the centuximab-sEGFR complex has been solved (Li et al. 2005). Additionally, it 
has recently been shown that cetuximab is ineffective in patients with K-ras mutations, 
providing an effective screening tool for oncology patients (Ramos et al. 2008). Rituximab 
(marketed under the trade name Rituxan®) is also a humanized chimeric mouse monoclonal 
antibody, but it is directed against the CD20 cell surface protein. CD20 is a transmembrane 
phosphoprotein expressed on the surface of the B-cells of the immune system (Perosa et al. 
2005). Rituximab is used medicinally for the treatment of non-Hodgkin’s lymphomas (i.e. 
various B-cell leukemias and lymphomas) (Sacchi et al. 2001). 
Both of these antibodies are used prevalently in their respective oncology settings, and 
therefore were good candidates to evaluate as model proteins. Here we present data from 
the development of two immunoassays along with the subsequent use of the immunoassays 
to support a full protein-container compatibility study. 
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2. Materials and methods 
2.1 Cetuximab immunoassay  
A recombinantly expressed sEGFR domain is commercially available (Fitzgerald Industries 
International) and we developed an antibody capture ELISA using this domain. Microtiter 
plates (Costar® high-bind 8-well strips) were coated overnight at 4 °C with 100 μL/well of 1 
μg/mL sEGFR reconstituted in 200 mM Na2CO3, pH 9.6. The coating solution was 
subsequently discarded and the plate was washed once with PBS-T (Phosphate Buffered 
Saline with 0.5% Tween® 20). The plates were then blocked with 200 μL/well of PBS-1% 
BSA (bovine serum albumin), sealed and stored at 4 °C until use. BSA only control plates 
were prepared by blocking uncoated plate strips with PBS-1% BSA as above. The required 
number of plate strips were removed from storage at 4 °C and allowed to reach room 
temperature prior to use. Dilutions of cetuximab (from the 2 mg/mL formulation 
concentration) were prepared in a range of 1:10-1:4096000 by serial dilution with PBS-0.5% 
BSA. The plate strips were washed three times with PBS-T. The dilutions were then added 
to the strips, in duplicate or triplicate, at 100 μL/well. The strips were then sealed and 
incubated at room temperature for one hour. During the incubation, a 1:5000 dilution of 
goat anti-human IgG-HRP secondary antibody (Sigma) was prepared in PBS-0.5% BSA by 
serial dilution. The strips were then washed three times with PBS-T and 100 μL/well of 
1:5000 secondary antibody was added. The strips were sealed and incubated for 1 hr at 
room temperature. The o-Phenylenediamine (OPD) substrate (Sigma) was then prepared by 
adding one OPD tablet and one buffer tablet to 20 mL of water. The strips were washed 
three times with PBS-T and 100 or 200 μL/well of OPD substrate was added. The strips were 
incubated 10 min at room temperature and the reaction was quenched with 50 μL/well of 
1M H2SO4. The plate was then read on a plate reader at 490 nm. The cetuximab standard 
curves were fit using a four parameter nonlinear regression model.  
Competition reactions using unbound sEGFR were also performed. A standard curve was 
prepared using serial dilutions of cetuximab ranging from 1:5000-1:320000 in PBS-0.5% BSA. 
A vial of lyophilized sEGFR (25 μg) was reconstituted at 100 ng/mL with water. Additional 
sEGFR stocks were prepared by serial dilution with PBS over a range of 20-0.0064 ng/μL. 
Competition reactions were prepared by combining 10 μL of sEGFR with 90 μL of 
cetuximab (diluted 1:50000 with PBS-0.5% BSA) for each concentration of sEGFR tested. The 
reactions were incubated for 10 min at room temperature. The entire volume of each 
reaction and the cetuximab standards were then used in the cetuximab ELISA procedure 
described above. 
2.2 Rituximab immunoassay 
Rituximab was labeled with fluorescein isothiocyanate (FITC; Sigma). Rituximab (0.7 mL @ 
~2.8 mg/mL) was labeled with 20 μL of 10 mg/mL FITC at room temperature for 2.25 hrs. 
The free FITC was removed via gel filtration with an EconoPac DG10 (BioRad) using Tris 
Buffered Saline (TBS) as the mobile phase. The pooled antibody had a concentration of 1.22 
mg/mL with an F/P ratio of 10.4. Rituximab was diluted serially with PBS-1% FBS (fetal 
bovine serum) to generate various dilutions. A 1:5000 stock of fluorescein labeled rituximab 
(FITC-rituximab) was prepared by serial dilution with PBS-1% FBS (fetal bovine serum) for 
www.intechopen.com
 
Trends in Immunolabelled and Related Techniques 
 
20
the competition assay. Whole blood was drawn from the same donor in heparin-coated 
vacutainers (BD) prior to each experiment. The competition experiments for each dilution of 
unlabeled rituximab were then prepared by combining 100 μL of whole blood with 10 μL of 
diluted unlabeled rituximab and 20 μL of diluted FITC-Rituximab. The reactions were 
vortexed and incubated at room temperature for 30 min in the dark. All reactions were 
vortexed again after the incubation and 2 mL of 1x lysis solution (BD) was added to each 
tube. The reactions were then incubated for 15 min at room temperature in the dark and 
spun down for 5 min at 3550 RPM. The supernatants were decanted and the cell pellets were 
washed with 2 mL of PBS-1% FBS. After spinning down the cells again as above, the 
supernatants were decanted and the cells were resuspended in 500 μL of PBS-1% FBS prior 
to analysis by flow cytometry on a BD FACScan cytometer. A forward-scatter and side-
scatter gate was established to isolate the lymphocyte population, and the mean fluorescent 
intensity value for this gate was calculated for each competition reaction. A standard curve 
was generated by serial dilution of a control rituximab sample in the competition reaction 
described above. The resulting standard curve was then used to interpolate the effective 
concentration value of the rituximab test samples. 
2.3 Assessment of flexible container compatibility 
Flexible film pouches were constructed using plastic film material and filled with 2 mL of 
antibody solution (cetuximab was formulated at 2 mg/mL and rituximab was formulated at 
10 mg/mL). Glass vials were also filled in the same manner to serve as controls. The 
containers were sealed in a laminar flow hood, using a bench-top impulse sealer for the 
pouches. After filling, the units were stored at the temperatures listed in Tables 2 and 3. 
Samples were removed from storage at the time points indicated and the contents of the 
pouches were analyzed. This analysis included standard physical and chemical testing, and 
running a bioassay to determine the activity of the protein (as described above for 
cetuximab and rituximab). 
 
Container Testing Schedule 
Temp. (C) 2 week 4 week 8 week 16 week
Film 1 5   X 2X 
25  X X X 
40 X X X X 
Film 2 5   X 2X 
25  X X X 
40 X X X X 
Glass 
Control 
5   X 2X 
25  X X X 
40 X X X X 
Table 1. Testing Matrix for Cetuximab Samples 
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Container Temp. (C)
Testing Schedule 
0 days 3 days 1 week 2 weeks 4 weeks 8 weeks 
Film 1 
 
5 X   X X X 
25   X X X X 
40  X X X X  
Film 2 
 
5 X   X X X 
25   X X X X 
40  X X X X  
Film 3 
 
5 X   X X X 
25   X X X X 
40  X X X X  
Film 4 
 
5 X   X X X 
25   X X X X 
40  X X X X  
Glass Control 5 X    X X 
Table 2. Testing Matrix for Rituximab Samples 
 
 
Fig. 1. Specificity of the cetuximab for sEGFR versus BSA 
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3. Results and discussion 
3.1 Cetuximab immunoassay development 
An immunoassay was developed for cetuximab, using commercially available sEGFR as the 
bound antigen for antibody capture. As shown in Figure 1, cetuximab has a specific 
response to sEGFR-coated strips with minimal background binding to BSA-only coated 
strips. A typical sigmoidal response was observed over a dilution range of 1:1000-1:4096000 
of cetuximab.  
The precision of the cetuximab ELISA was then examined over three independent 
experiments. Quadruplicate 1:50000 cetuximab dilutions (serially diluted with PBS-0.5% 
BSA) were prepared and analyzed in each experiment. The dilutions of the cetuximab 
standards were also varied across these experiments to determine the optimal range of 
concentrations for maximum linear response. All standards were run in triplicate and all test 
samples (1:50000 replicate dilutions) were run in duplicate. The optimal range for the 
cetuximab standard curve was ~1:5000-1:2000000 (typical standard curve is shown in Figure 
2). The standards also had well-to-well CVs < 15% in all three experiments. The cetuximab 
standard curves were fit as described in the procedure and the concentrations were 
calculated for the 1:50000 diluted samples. The intraexperimental replicate variance (%CV) 
for the quadruplicate 1:50000 dilutions ranged from 8.6-12.8%. Additionally, the 
interexperimental variance (%CV) for the average calculated concentration for the 1:50000 
diluted cetuximab samples from the three experiments was 14.2%. The average 
concentration across the three experiments, 39.6 ng/mL, was very near the expected value 
of 40 ng/mL for a 1:50000 dilution of the neat cetuximab formulated at 2 mg/mL.  
 
 
Fig. 2. Typical cetuximab standard curve for the sEGFR based ELISA 
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A competition experiment was also performed using free sEGFR in the ELISA assay as 
described in the Materials and Methods section. As shown in Figure 3, the percentage of 
cetuximab bound dropped to less than 5% with 10 ng/μL of free sEGFR and the observed 
IC50 was between 1-2 ng/μL or 12.5-25 nM. This result is comparable to the published Kd of 
2.3 ± 0.5 nM for cetuximab binding to sEGFR via Biacore (Li et al. 2005).  
 
Fig. 3. Competition experiment using sEGFR titrated into the sEGFR ELISA 
Cetuximab had a consistent response towards sEGFR in this ELISA based assay with 
minimal background binding to BSA. Across three independent experiments, the 
intraexperimental and interexperimental CVs were all < 15%, which is typical for most 
ELISA based assays. Additionally, free sEGFR was able to completely inhibit binding to the 
sEGFR coated plates and the observed Kd for sEGFR was similar to published results. 
Overall, the assay appeared to be adequate to serve as a bioassay for cetuximab. 
3.2 Cetuximab container compatibility 
Test articles were prepared consisting of pouches made of plastic films filled with cetuximab 
protein formulation (2 mL fill at 2 mg/mL). Additionally, glass vials were filled with 
cetuximab (2 mL fill) to serve as controls. The sampling time points and incubation 
conditions are summarized in Table 1.  
The binding activity of cetuximab was monitored over the course of the study using the 
ELISA assay described here. The results are shown in Figures 4A-C, where the error bars 
represent plus or minus one standard deviation from the mean of triplicate assays of a single 
sample. The glass controls were used to normalize the ELISA data and these results were all 
well within the range of the assay variance (<15% CV). The physical and chemical test data 
(S. E. Lee, et al., in preparation) showed that cetuximab solution held in plastic containers 
behaved similarly to cetuximab solution held in glass vials. These data suggest that 
cetuximab solution is compatible with both Film 1 as well as Film 2. 
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Fig. 4A. Immunoassay results for the various cetuximab test articles at 5 °C 
 
Fig. 4B. Immunoassay results for the various cetuximab test articles at 25 °C 
3.3 Rituximab immunoassay development 
Since CD20 extracellular domain was not commercially available for the development of an 
ELISA-based assay, a cell-based immunoassay was developed to evaluate the binding of 
rituximab to the CD20 cell surface receptor on B-cells. This assay format has the advantage of 
observing the direct binding of rituximab to the CD20 receptors on B-cells in the more 
physiological context of whole blood (as compared to ELISA-based approaches). Whole blood  
(5 oC)
(25 oC)
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Fig. 4C. Immunoassay results for the various cetuximab test articles at 40 °C 
was drawn from the same single donor at each time point throughout the study to serve as the 
source of B-cells. A competitive assay format was utilized for the immunoassay by titrating an 
unlabeled rituximab antibody standard against a constant concentration of FITC-labeled 
rituximab. A typical competitive response curve is shown in Figure 5, using a 1:5000 dilution 
of the FITC-rituximab. At each testing time point (as described in Table 2) a competitive 
standard curve was established based on the observed mean fluorescence intensity (MFI) for 
each dilution of the rituximab standard. The test articles were each diluted 1:2000 (to fall 
approximately at the midpoint of the standard curve) and the observed MFI value for each test 
article was used to interpolate a concentration value relative to the rituximab standard.  
3.4 Rituximab container compatibility 
To generate the samples for this study, rituximab solution was pipetted into pouches made from 
four different flexible films and then the pouches were sealed using a heat sealer. Care was taken 
to avoid dripping protein solution into the area where the final seal was formed. The sealed 
pouches were incubated at either 5 C, 25 C, or 40 C, as indicated in Table 2. Glass controls 
were maintained at 5 C for the duration of the study. Samples were removed from storage and 
the contents of the pouches were analyzed to determine the physical and chemical stability of 
the formulation and running an immunoassay to determine the activity of the protein. 
Rituximab binding activity was assayed using the whole blood competitive binding 
immunoassay described here. The data shown here have been corrected using the apparent 
protein concentrations determined from SEC-MALLS data (S. E. Lee, et al., in preparation). 
These data indicate that there is little decrease in binding activity over the course of the 
study and that there is no significant differentiation among the four film types tested in this 
study (Figures 6A-C). There was day-to-day variation in the normalized concentrations of 
the test samples, which is likely inherent to the competition assay used. At most time points,  
(40 oC)
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Fig. 5. Typical standard curve for the rituximab competitive cell binding immunoassay 
 
Fig. 6A. Immunoassay results for rituximab test articles at 5 °C (results normalized to the 5 
°C glass controls) 
all films were clustered in terms of effective concentration and the average effective 
concentration varied approximately  10% from normal for the 5 C and 25 C storage 
conditions. This was not the case for the 40 C storage condition, as other samples from the 
same testing interval had higher effective concentrations. These data indicate a slight 
downward trend in bioactivity in the samples stored at 40 C for 4 weeks.  
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Fig. 6B. Immunoassay results for rituximab test articles at 25 °C (results normalized to the 5 
°C glass controls) 
 
Fig. 6C. Immunoassay results for rituximab test articles at 40 °C (results normalized to the  
5 °C glass controls) 
The results of this study show that Rituximab solution is compatible with all four film types 
tested. Bioactivity assays confirm that the protein behaves similarly in all four film types over 
the course of the study, despite a slight decrease in activity upon storage for 4 weeks at 40 C.  
4. Conclusion 
The primary aim of this study was to develop and implement protein-specific 
immunoassays to support the evaluation of the compatibility of two protein biotherapeutics 
with plastic RTU prototype containers. Here we have demonstrated, through the use of in-
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house developed immunoassays and standard chemical and chromatographic techniques, 
that flexible plastic containers can have equivalent performance to standard glass vials. This 
observation was true both in terms of the observed binding activities and the physical and 
chemical data collected (S. E. Lee, et al., in preparation) for the two monoclonal antibodies 
tested, cetuximab and rituximab. Establishing this compatibility is essential to enabling a 
shift to this type of container system in the healthcare sector. Flexible plastic RTU containers 
provide a more convenient format for dosing to the patient, they can reduce medication 
errors by providing a ready to infuse format and also pose a lower risk of injury to both 
healthcare workers and patients. As the number of commercialized biotherapeutics 
increases, the need for these types of container systems becomes readily apparent. The 
methodology used in these studies can be used as a guideline for compatibility evaluations 
of other types of therapeutic proteins. As more types of biotherapeutic products make their 
way to market, there will be an increasing need for biological assays to assess their potency. 
The work described here illustrates the importance of using specifically tailored 
immunoassays to assess the activity of biotherapeutics selected for use as model proteins. 
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